Publications by authors named "Y Sagna"
Article Synopsis
- * Out of 1330 individuals, 1200 consented to participate; the study found a T2DM prevalence of 10.74%, and identified significant risk factors including age, family history of diabetes, obesity, and hypertension.
- * The findings highlight the need for a national program in Burkina Faso to control diabetes and promote early detection to manage and prevent complications effectively.
Aim: There are no data on type 1 diabetes (T1D) incidence and prevalence in Burkina Faso. We aimed to determine these in persons aged <25 years (y) since the implementation of Life for a Child (LFAC) program in 2013.
Patients And Methods: Data were collected from the prospective program register.
Background: Type 1 diabetes (T1D) in youth is becoming a public health problem in Sub-Saharan Africa, including Burkina Faso. However, little is known about the level of knowledge of these patients on T1D. This study aimed to evaluate the knowledge of diabetes in adolescents and young adults about the disease, and identify the factors associated in Burkina Faso.
View Article and Find Full Text PDFComparison of regular with NPH insulin vs. premix insulin in children and adolescents with type 1 diabetes in a resources-limited setting: a retrospective data analysis.
J Pediatr Endocrinol Metab
May 2023
Objectives: Few studies addressed the efficacy of human insulin regimens (mostly premix insulin) used in many low-and-middle income countries on glycemic control of children and adolescents with diabetes. The aim of this study was to assess the efficacy of the premix insulin on the glycated hemoglobin (HbA) in comparison to the regular with NPH insulin scheme.
Methods: A retrospective study was carried out from January 2020 to September 2022 on patients with type 1 diabetes aged below 18 years followed in Burkina Life For A Child program.
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of growth hormone (GH) replacement therapy in adults with Langerhans cell histiocytosis (LCH) who also have growth hormone deficiency (GHD), using data from the Pfizer International Metabolic Database (KIMS).
- Out of 81 patients analyzed, one year of GH treatment showed improvements in metabolic parameters like reduced total cholesterol and increased quality of life scores, with 37 patients providing follow-up data.
- The safety analysis revealed 36 serious adverse events over 435 patient-years, but no new safety concerns were identified, suggesting that GH treatment is safe and effective for this population.